Table 1.

Results of complement analyses after eculizumab (1 × 600 mg)^a

Day	APH50 (%)	C3 (mg/ml)	C3d (mU/L)	SC5b-9 (ng/ml)
1	<5	0.70	48	634
3	nt	0.83	37	728
7	49	1.19	19	575
10	nt	1.00	58	392
13	134	1.47	56	360
17	nt	1.09	49	369
21	114	0.91	49	309
24	nt	0.76	56	256

^ant, not tested.